Corona Remedies FY26 Annual Earnings Summary

The new hormonal plant's commercial production and WHO/EU GMP approvals are expected only by FY27-end; any delay could push international revenue contribution further out.

PCPM for reps with 0-3 years experience is only ₹2-2.5 lakh vs. ₹8 lakh for tenured reps; rapid MR addition (5-7% annually) could pressure overall productivity.

Management plans to enter infertility, spine, CNS, etc., but has not provided specific timelines or investment details beyond infertility; competitive intensity may limit success.

Employee costs remain high due to addition of 600 MRs over three years; margins may take time to reach peer levels.

Management acknowledged possible higher distribution costs in Q4 due to GLP-1 launch, which could compress margins.

The IVF portfolio from Bayer requires cold chain management and specialist detailing; success depends on adoption by 3,000 centers.

Geopolitical tensions may increase API prices, impacting gross margins. Management noted indirect impact but expects to manage within 80% gross margin band.

Wokadin acquisition may cause ~400bps gross margin correction in first year due to NLEM portfolio. Management expects 25% revenue growth but margin recovery uncertain.

Management is evaluating two brand acquisitions but noted low conversion probability, leaving growth partly dependent on organic efforts.

New infertility and multispecialty divisions, plus biosimilar launches, require ramp-up time. PCPM for new hires takes 3+ years to mature.